p53 but not erbB-2 expression is associated with rapid tumor proliferation in urinary bladder cancer

Steinmever, 1988, DNA binding properties of murine p53, Oncogene, 3, 501 Baker, 1990, Suppression of human colorectal carcinoma cell growth by wild-type p53, Science, 249, 912, 10.1126/science.2144057 Eliyahu, 1989, Wild-type p53 can inhibit oncogene-mediated focus formation, 86, 8763 Isaacs, 1991, Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles, Cancer Res, 51, 4716 Finlay, 1988, Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life, Mol Cell Biol, 8, 531, 10.1128/MCB.8.2.531 Milner, 1991, Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation, Cell, 65, 765, 10.1016/0092-8674(91)90384-B Milner, 1991, Tumor suppressor p53: Analysis of wild-type and mutant p53 complexes, Mol Cell Biol, 11, 12, 10.1128/MCB.11.1.12 Marks, 1991, Overexpression and mutation of p53 in epithelial ovarian cancer, Cancer Res, 51, 2979 Iggo, 1990, Increased expression of mutant forms of p53 oncogene in primary lung cancer, Lancet, 335, 675, 10.1016/0140-6736(90)90801-B Bartek, 1990, Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines, Oncogene, 5, 893 Levine, 1989, The p53 tumor suppressor gene and gene product, 20, 221 Sarkis, 1993, Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression, J Natl Cancer Inst, 85, 53, 10.1093/jnci/85.1.53 Moch, 1993, p53 And erbB-2 protein overexpression are early stage alterations in transitional cell carcinoma of the bladder, Virchows Arch A Pathol Anat Histopathol, 423, 329, 10.1007/BF01607144 Dalbagni, 1993, Molecular genetic alterations of chromosome 17 and p53 nuclear overexpression in human bladder cancer, Diagn Mol Path, 2, 4, 10.1097/00019606-199303000-00002 Hsuan, 1989, Structural basis for epidermal growth factor receptor function, Prog Growth Factor Res, 1, 23, 10.1016/0955-2235(89)90039-2 McCann, 1991, Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer, Cancer Res, 51, 3296 Kallioniemi, 1991, Association of c-erbB-2 protein overexpression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer, Int J Cancer, 49, 650, 10.1002/ijc.2910490504 Lovekin, 1991, c-erbB-2 Oncoprotein expression in primary and advanced breast cancer, Br J Cancer, 63, 439, 10.1038/bjc.1991.101 Yonemura, 1991, Expression of c-erbB-2 oncoprotein in gastric carcinoma. Immunoreactivity for c-erbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma, Cancer, 67, 2914, 10.1002/1097-0142(19910601)67:11<2914::AID-CNCR2820671134>3.0.CO;2-G Ueda, 1992, New prognostic factors in patients with esophageal squamous carcinoma, Gan To Kagaku Ryoho, 19, 20 Stenman, 1991, Expression of the ERBB2 protein in benign and malignant salivary gland tumors, Genes Chromosom Cancer, 3, 128, 10.1002/gcc.2870030208 Sauter, 1993, Heterogeneity of erbB-2 gene amplification in bladder cancer, Cancer Res, 53, 2199 Stumpp, 1992, Growth fraction in breast carcinoma determined by Ki-67 immunostaining: Correlation with pathological and clinical variables, Gynecol Obstet Invest, 33, 47, 10.1159/000294846 Lee, 1992, DNA ploidy, proliferation, and neu-oncogene protein overexpression in breast carcinoma, Mod Pathol, 5, 61 Pavelic, 1992, c-myc, c-erbB-2, And Ki-67 expression in normal breast tissue and in invasive and noninvasive breast carcinoma, Cancer Res, 52, 2597 Gasparini, 1991, Breast cancer cell linetics: Immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness, Anticancer Res, 11, 2015 Yamada, 1991, Prognostic significance of the proportion of Ki-67-positive cells in adult T-cell leukemia, Cancer, 67, 2605, 10.1002/1097-0142(19910515)67:10<2605::AID-CNCR2820671034>3.0.CO;2-L Sahin, 1991, Ki-67 immunostaining in node-negative stage III breast carcinoma. Significant correlation with prognosis, Cancer, 68, 549, 10.1002/1097-0142(19910801)68:3<549::AID-CNCR2820680318>3.0.CO;2-J Ueda, 1989, Prognostic significance of Ki-67 reactivity in soft tissue sarcomas, Cancer, 63, 1607, 10.1002/1097-0142(19890415)63:8<1607::AID-CNCR2820630827>3.0.CO;2-1 Cattoretti, 1992, Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections, J Pathol, 168, 357, 10.1002/path.1711680404 International Union Against Cancer, 1978 Mostofi, 1973 Hsu, 1981, Use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase techniques: A comparison study between ABC and unlabeled antibody (PAP) procedures, J Histochem Cytochem, 29, 577, 10.1177/29.4.6166661 Carbin, 1991, Grading of human urothelial carcinoma based on nuclear atypia and mitotic frequency. II. Prognostic importance, J Urol, 145, 972, 10.1016/S0022-5347(17)38503-8 Waldman, 1993, BrdUrd incorporation and PCNA expression as measures of cell proliferation in transitional cell carcinoma of the urinary bladder, Mod Pathol, 6, 20 Tsujihashi, 1991, Cell proliferation of human bladder tumors determined by BrdUrd and Ki-67 immunostaining, J Urol, 145, 846, 10.1016/S0022-5347(17)38475-6 Mulder, 1992, Prognostic factors in bladder carcinoma: Histologic parameters and expression of a cell cycle related nuclear antigen (Ki-67), J Pathol, 166, 37, 10.1002/path.1711660107 Okamura, 1990, Growth fractions of transitional cell carcinomas of the bladder defined by the monoclonal antibody Ki-67, J Urol, 144, 875, 10.1016/S0022-5347(17)39613-1 Lipponen, 1992, Cell proliferation of transitional cell bladder cancer determined by PCNA/cyclin immunostaining. A histopathological description, Anticancer Res, 12, 577 Shaaban, 1990, Prediction of lymph node metastasis with deoxyribonucleic acid flow cytometry, J Urol, 144, 884, 10.1016/S0022-5347(17)39615-5 Lipponen, 1991, Prognosis of transitional bladder cancer: A multivariate prognostic score for improved prediction, J Urol, 145, 225 Lipponen, 1991, Progression and survival in transitional cell bladder cancer: A comparison of established factors, S-phase fraction and DNA ploidy, Eur J Cancer, 27, 877, 10.1016/0277-5379(91)90138-4 Lipponen, 1991, Classic prognostic factors, flow cytometric data, nuclear morphometric variables and mitotic indexes as predictors in transitional cell bladder cancer, Anticancer Res, 11, 911 Leonardi, 1992, PCNA and Ki67 expression in breast carcinoma: Correlations with clinical and biological variables, J Clin Pathol, 45, 416, 10.1136/jcp.45.5.416 Isola, 1992, Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients, J Natl Cancer Inst, 84, 1109, 10.1093/jnci/84.14.1109 Cattoretti, 1988, p53 Expression in breast cancer, Int J Cancer, 41, 178, 10.1002/ijc.2910410204 Campo, 1991, Loss of heterozygosity of p53 gene and p53 protein expression in human colorectal carcinomas, Cancer Res, 51, 4436 Pignatelli, 1992, Over-expression of p53 nuclear oncoprotein in colorectal adenomas, Int J Cancer, 50, 683, 10.1002/ijc.2910500503 Scott, 1991, p53 In colorectal cancer: Clinicopathological correlation and prognostic significance, Br J Cancer, 63, 317, 10.1038/bjc.1991.74 Visakorpi, 1992, Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation, J Natl Cancer Inst, 84, 883, 10.1093/jnci/84.11.883 Barbareschi, 1992, p53 Protein expression in central nervous system neoplasms, J Clin Pathol, 45, 583, 10.1136/jcp.45.7.583 Morkve, 1991, Flow cytometric measurement of p53 protein expression and DNA content in paraffin-embedded tissue from bronchial carcinomas, Cytometry, 12, 438, 10.1002/cyto.990120509 Sauter, 1994, Physical deletion of the p53 gene in bladder cancer: Detection by fluorescence in situ hybridization, Am J Pathol, 144, 756 Kastan, 1991, Participation of p53 protein in the cellular response to DNA damage, Cancer Res, 51, 6304 Masters, 1989, DNA ploidy and the prognosis of stage pT1 bladder cancer, Br J Urol, 64, 403, 10.1111/j.1464-410X.1989.tb06052.x Bilous, 1992, Immunocytochemistry and in situ hybridisation of epidermal growth factor receptor and relation to prognostic factors in breast cancer, Eur J Cancer, 28A, 1033, 10.1016/0959-8049(92)90449-C Sauter, 1994, Epidermal growth factor receptor expression is associated with rapid tumor proliferation in bladder cancer, Int J Cancer, 57, 508, 10.1002/ijc.2910570412 Toi, 1990, Relationship between epidermal growth factor receptor status and various prognostic factors in human breast cancer, Cancer, 65, 1980, 10.1002/1097-0142(19900501)65:9<1980::AID-CNCR2820650917>3.0.CO;2-U